Birdwatch Note
2024-12-21 03:54:55 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
動画6:27のあたりにある回答は、重篤な副反応が認められていない、ではなく、重大な懸念は認められていない、なので誤解を招く投稿です。 https://x.com/i/broadcasts/1MYGNMVNWLvKw 重篤な副反応は極めて稀で安全性の基準を満たすというのは下記の世界中の専門機関で一致して同様の評価されています。 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice#:~:text=COVID%2D19%20vaccines%20are%20safe.&text=New%20versions%20of%20the%20vaccine,doses%20have%20been%20administered%20globally. https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines/safety-covid-19-vaccines#:~:text=The%20safety%20profiles%20of%20the,few%20of%20these%20rare%20cases. https://www.cdc.gov/vaccine-safety/vaccines/covid-19.html https://www.nhs.uk/vaccinations/covid-19-vaccine/#:~:text=COVID%2D19%20vaccine%20safety,products%20Regulatory%20Agency%20(MHRA). 救済制度の数が、なぜ安全性の評価とは繋がらないかというと、この制度は迅速な救済が目的で、"接種で症状が起きる事を否定できない場合"も救済の対象で https://www.mhlw.go.jp/content/10900000/000864824.pdf#page=3 かなり広く網をはっているためと厚労大臣に説明されています。 https://www.mhlw.go.jp/stf/kaiken/daijin/0000194708_00744.html 審査員も、明らかに否定できる場合以外を極力救済と説明されています。 https://www.asahi.com/articles/ASRCQ53XCRCPUTFL01H.html
Written by 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1870231484164198754
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1870316995968901211
- noteId - 1870316995968901211
- participantId -
- noteAuthorParticipantId - 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE Participant Details
- createdAtMillis - 1734753295305
- tweetId - 1870231484164198754
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 1
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 動画6:27のあたりにある回答は、重篤な副反応が認められていない、ではなく、重大な懸念は認められていない、なので誤解を招く投稿です。 https://x.com/i/broadcasts/1MYGNMVNWLvKw 重篤な副反応は極めて稀で安全性の基準を満たすというのは下記の世界中の専門機関で一致して同様の評価されています。 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice#:~:text=COVID%2D19%20vaccines%20are%20safe.&text=New%20versions%20of%20the%20vaccine,doses%20have%20been%20administered%20globally. https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines/safety-covid-19-vaccines#:~:text=The%20safety%20profiles%20of%20the,few%20of%20these%20rare%20cases. https://www.cdc.gov/vaccine-safety/vaccines/covid-19.html https://www.nhs.uk/vaccinations/covid-19-vaccine/#:~:text=COVID%2D19%20vaccine%20safety,products%20Regulatory%20Agency%20(MHRA). 救済制度の数が、なぜ安全性の評価とは繋がらないかというと、この制度は迅速な救済が目的で、"接種で症状が起きる事を否定できない場合"も救済の対象で https://www.mhlw.go.jp/content/10900000/000864824.pdf#page=3 かなり広く網をはっているためと厚労大臣に説明されています。 https://www.mhlw.go.jp/stf/kaiken/daijin/0000194708_00744.html 審査員も、明らかに否定できる場合以外を極力救済と説明されています。 https://www.asahi.com/articles/ASRCQ53XCRCPUTFL01H.html
Note Ratings
| rated at | rated by | |
| 2024-12-21 22:22:24 -0600 | Rating Details | |
| 2024-12-21 10:17:59 -0600 | Rating Details | |
| 2024-12-21 08:26:16 -0600 | Rating Details | |
| 2024-12-21 07:58:35 -0600 | Rating Details | |
| 2024-12-21 07:43:08 -0600 | Rating Details | |
| 2024-12-21 07:01:54 -0600 | Rating Details | |
| 2024-12-21 05:04:09 -0600 | Rating Details | |
| 2024-12-21 04:28:51 -0600 | Rating Details | |
| 2024-12-21 03:43:50 -0600 | Rating Details | |
| 2024-12-21 03:04:06 -0600 | Rating Details | |
| 2024-12-21 03:00:08 -0600 | Rating Details | |
| 2024-12-21 02:42:32 -0600 | Rating Details | |
| 2024-12-21 02:37:58 -0600 | Rating Details | |
| 2024-12-21 01:58:09 -0600 | Rating Details | |
| 2024-12-21 01:52:06 -0600 | Rating Details | |
| 2024-12-21 01:39:28 -0600 | Rating Details | |
| 2024-12-21 01:37:44 -0600 | Rating Details | |
| 2024-12-21 01:32:53 -0600 | Rating Details | |
| 2024-12-21 01:20:59 -0600 | Rating Details | |
| 2024-12-21 00:03:30 -0600 | Rating Details | |
| 2024-12-20 22:01:33 -0600 | Rating Details | |
| 2024-12-20 22:01:15 -0600 | Rating Details | |
| 2024-12-20 21:55:54 -0600 | Rating Details | |
| 2024-12-21 07:47:45 -0600 | Rating Details | |
| 2024-12-21 05:28:59 -0600 | Rating Details | |
| 2024-12-21 05:28:38 -0600 | Rating Details | |
| 2024-12-21 03:57:29 -0600 | Rating Details | |
| 2024-12-21 03:49:55 -0600 | Rating Details | |
| 2024-12-21 03:17:16 -0600 | Rating Details | |
| 2024-12-21 02:29:28 -0600 | Rating Details | |
| 2024-12-21 01:29:54 -0600 | Rating Details | |
| 2024-12-21 01:07:05 -0600 | Rating Details | |
| 2024-12-21 11:06:32 -0600 | Rating Details | |
| 2024-12-21 08:47:28 -0600 | Rating Details | |
| 2024-12-21 05:18:46 -0600 | Rating Details | |
| 2024-12-21 03:03:19 -0600 | Rating Details | |
| 2024-12-20 22:20:13 -0600 | Rating Details | |
| 2024-12-20 21:57:38 -0600 | Rating Details |